JP5785073B2 - 家畜の呼吸系と生殖系の感染症に対するワクチン - Google Patents
家畜の呼吸系と生殖系の感染症に対するワクチン Download PDFInfo
- Publication number
- JP5785073B2 JP5785073B2 JP2011275303A JP2011275303A JP5785073B2 JP 5785073 B2 JP5785073 B2 JP 5785073B2 JP 2011275303 A JP2011275303 A JP 2011275303A JP 2011275303 A JP2011275303 A JP 2011275303A JP 5785073 B2 JP5785073 B2 JP 5785073B2
- Authority
- JP
- Japan
- Prior art keywords
- bvdv
- leptospira
- virus
- vaccine
- day
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 229960005486 vaccine Drugs 0.000 title claims description 120
- 208000015181 infectious disease Diseases 0.000 title claims description 60
- 230000000241 respiratory effect Effects 0.000 title claims description 10
- 244000144972 livestock Species 0.000 title description 35
- 230000001850 reproductive effect Effects 0.000 title description 4
- 241000710780 Bovine viral diarrhea virus 1 Species 0.000 claims description 206
- 241000283690 Bos taurus Species 0.000 claims description 190
- 235000013365 dairy product Nutrition 0.000 claims description 125
- 241000700605 Viruses Species 0.000 claims description 101
- 241000589902 Leptospira Species 0.000 claims description 85
- 241001465754 Metazoa Species 0.000 claims description 59
- 239000000203 mixture Substances 0.000 claims description 51
- 238000000034 method Methods 0.000 claims description 46
- 244000309466 calf Species 0.000 claims description 42
- 230000001605 fetal effect Effects 0.000 claims description 31
- 230000002163 immunogen Effects 0.000 claims description 27
- 239000000427 antigen Substances 0.000 claims description 18
- 102000036639 antigens Human genes 0.000 claims description 18
- 108091007433 antigens Proteins 0.000 claims description 18
- 230000013011 mating Effects 0.000 claims description 17
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 16
- 241000589876 Campylobacter Species 0.000 claims description 10
- 241001550390 Leptospira interrogans serovar Canicola Species 0.000 claims description 9
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims description 9
- 229930182490 saponin Natural products 0.000 claims description 9
- 150000007949 saponins Chemical class 0.000 claims description 9
- 235000012000 cholesterol Nutrition 0.000 claims description 8
- 230000002085 persistent effect Effects 0.000 claims description 8
- 241000589927 Leptospira borgpetersenii Species 0.000 claims description 7
- 241000530623 Bovine viral diarrhea virus 2 Species 0.000 claims description 6
- 241000178947 Leptospira interrogans serovar Pomona Species 0.000 claims description 6
- 239000002480 mineral oil Substances 0.000 claims description 6
- 239000007764 o/w emulsion Substances 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 4
- 241001293418 Mannheimia haemolytica Species 0.000 claims description 4
- 239000000839 emulsion Substances 0.000 claims description 4
- 239000000787 lecithin Substances 0.000 claims description 4
- 229940067606 lecithin Drugs 0.000 claims description 4
- 235000010445 lecithin Nutrition 0.000 claims description 4
- 235000010446 mineral oil Nutrition 0.000 claims description 4
- 241001138504 Mycoplasma bovis Species 0.000 claims description 3
- 241001147662 Neospora caninum Species 0.000 claims description 3
- 241000224526 Trichomonas Species 0.000 claims description 3
- 244000309465 heifer Species 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 241000606831 Histophilus somni Species 0.000 claims description 2
- 241000712003 Human respirovirus 3 Species 0.000 claims 4
- 229930182558 Sterol Natural products 0.000 claims 4
- 150000003432 sterols Chemical class 0.000 claims 4
- 235000003702 sterols Nutrition 0.000 claims 4
- PPBOKXIGFIBOGK-BDTUAEFFSA-N bvdv Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)C(C)C)[C@@H](C)CC)C1=CN=CN1 PPBOKXIGFIBOGK-BDTUAEFFSA-N 0.000 claims 3
- 241001529453 unidentified herpesvirus Species 0.000 claims 2
- 241000606860 Pasteurella Species 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000003754 fetus Anatomy 0.000 description 102
- 238000002955 isolation Methods 0.000 description 49
- 229940068196 placebo Drugs 0.000 description 35
- 239000000902 placebo Substances 0.000 description 35
- 239000002671 adjuvant Substances 0.000 description 30
- 238000012360 testing method Methods 0.000 description 30
- 208000005562 infectious bovine rhinotracheitis Diseases 0.000 description 28
- 229940001442 combination vaccine Drugs 0.000 description 24
- 210000002966 serum Anatomy 0.000 description 24
- 210000004381 amniotic fluid Anatomy 0.000 description 22
- 238000002255 vaccination Methods 0.000 description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 21
- 238000007918 intramuscular administration Methods 0.000 description 21
- 208000000995 spontaneous abortion Diseases 0.000 description 21
- 238000007920 subcutaneous administration Methods 0.000 description 21
- 241000701083 Bovine alphaherpesvirus 1 Species 0.000 description 20
- 206010000234 Abortion spontaneous Diseases 0.000 description 19
- 241000711895 Bovine orthopneumovirus Species 0.000 description 19
- 239000008280 blood Substances 0.000 description 19
- 201000010099 disease Diseases 0.000 description 19
- 210000004369 blood Anatomy 0.000 description 18
- 210000003734 kidney Anatomy 0.000 description 17
- 230000035935 pregnancy Effects 0.000 description 17
- 210000002700 urine Anatomy 0.000 description 17
- 206010058874 Viraemia Diseases 0.000 description 16
- 238000011081 inoculation Methods 0.000 description 16
- 238000003364 immunohistochemistry Methods 0.000 description 15
- 238000004113 cell culture Methods 0.000 description 14
- 230000000120 cytopathologic effect Effects 0.000 description 14
- 208000015994 miscarriage Diseases 0.000 description 14
- 206010024238 Leptospirosis Diseases 0.000 description 13
- 230000004044 response Effects 0.000 description 12
- 230000000405 serological effect Effects 0.000 description 12
- 230000036039 immunity Effects 0.000 description 11
- 230000003053 immunization Effects 0.000 description 11
- 238000003556 assay Methods 0.000 description 10
- 210000001508 eye Anatomy 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 230000028993 immune response Effects 0.000 description 9
- 238000006386 neutralization reaction Methods 0.000 description 9
- 230000001681 protective effect Effects 0.000 description 9
- 230000009467 reduction Effects 0.000 description 9
- 238000011156 evaluation Methods 0.000 description 8
- 238000002649 immunization Methods 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 210000005259 peripheral blood Anatomy 0.000 description 7
- 239000011886 peripheral blood Substances 0.000 description 7
- 208000023504 respiratory system disease Diseases 0.000 description 7
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 6
- 238000010240 RT-PCR analysis Methods 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000005856 abnormality Effects 0.000 description 6
- 239000002054 inoculum Substances 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 231100000331 toxic Toxicity 0.000 description 6
- 230000002588 toxic effect Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 208000031295 Animal disease Diseases 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 241000191940 Staphylococcus Species 0.000 description 5
- 230000002238 attenuated effect Effects 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 210000002826 placenta Anatomy 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 210000001541 thymus gland Anatomy 0.000 description 5
- 238000004448 titration Methods 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- 235000009027 Amelanchier alnifolia Nutrition 0.000 description 4
- 244000068687 Amelanchier alnifolia Species 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 206010057190 Respiratory tract infections Diseases 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 4
- 229940024545 aluminum hydroxide Drugs 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000001332 colony forming effect Effects 0.000 description 4
- 230000012173 estrus Effects 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 210000003736 gastrointestinal content Anatomy 0.000 description 4
- 238000012151 immunohistochemical method Methods 0.000 description 4
- 230000002779 inactivation Effects 0.000 description 4
- 230000002458 infectious effect Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 238000002559 palpation Methods 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 210000004910 pleural fluid Anatomy 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 208000032484 Accidental exposure to product Diseases 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 238000000729 Fisher's exact test Methods 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 3
- 206010028851 Necrosis Diseases 0.000 description 3
- 241000606856 Pasteurella multocida Species 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 208000037581 Persistent Infection Diseases 0.000 description 3
- 241000710778 Pestivirus Species 0.000 description 3
- 206010035664 Pneumonia Diseases 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 206010051511 Viral diarrhoea Diseases 0.000 description 3
- NKVLDFAVEWLOCX-GUSKIFEASA-N [(2s,3r,4s,5r,6r)-3-[(2s,3r,4s,5r,6s)-5-[(2s,3r,4s,5r)-4-[(2s,3r,4r)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy-3,5-dihydroxyoxan-2-yl]oxy-3,4-dihydroxy-6-methyloxan-2-yl]oxy-4,5-dihydroxy-6-methyloxan-2-yl] (4ar,5r,6as,6br,9s,10s,12ar)-10-[(2r,3r,4s, Chemical compound O([C@H]1[C@H](O)CO[C@H]([C@@H]1O)O[C@H]1[C@H](C)O[C@H]([C@@H]([C@@H]1O)O)O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](C)O[C@H]1OC(=O)[C@]12CCC(C)(C)CC1C1=CCC3[C@@]([C@@]1(C[C@H]2O)C)(C)CCC1[C@]3(C)CC[C@@H]([C@@]1(C)C=O)O[C@@H]1O[C@@H]([C@H]([C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)CO2)O)[C@H]1O[C@H]1[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O1)O)O)C(=O)NCCCCCCCCCCCC)[C@@H]1OC[C@](O)(CO)[C@H]1O NKVLDFAVEWLOCX-GUSKIFEASA-N 0.000 description 3
- 231100000818 accidental exposure Toxicity 0.000 description 3
- 229940037003 alum Drugs 0.000 description 3
- 238000002669 amniocentesis Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000017074 necrotic cell death Effects 0.000 description 3
- 229940051027 pasteurella multocida Drugs 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 210000002345 respiratory system Anatomy 0.000 description 3
- 238000013207 serial dilution Methods 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 210000004291 uterus Anatomy 0.000 description 3
- JDRAOGVAQOVDEB-KTKRTIGZSA-N (3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl) (z)-octadec-9-enoate Chemical compound OC1COC2C(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC21 JDRAOGVAQOVDEB-KTKRTIGZSA-N 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- 241000589874 Campylobacter fetus Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 208000037384 Clostridium Infections Diseases 0.000 description 2
- 208000003322 Coinfection Diseases 0.000 description 2
- 102100022477 DNA repair protein complementing XP-C cells Human genes 0.000 description 2
- 101000984570 Enterobacteria phage T4 Baseplate wedge protein gp53 Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 101000997743 Escherichia phage Mu Serine recombinase gin Proteins 0.000 description 2
- 206010048461 Genital infection Diseases 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 101000618535 Homo sapiens DNA repair protein complementing XP-C cells Proteins 0.000 description 2
- 101000640924 Homo sapiens SEC23-interacting protein Proteins 0.000 description 2
- 241001215120 Leptospirales Species 0.000 description 2
- 101001099926 Mus musculus Ankycorbin Proteins 0.000 description 2
- 101000618540 Mus musculus DNA repair protein complementing XP-C cells homolog Proteins 0.000 description 2
- 238000011887 Necropsy Methods 0.000 description 2
- 229940124679 RSV vaccine Drugs 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 230000024932 T cell mediated immunity Effects 0.000 description 2
- 206010047400 Vibrio infections Diseases 0.000 description 2
- 102100039414 WD repeat-containing protein 48 Human genes 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000000721 bacterilogical effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 208000035850 clinical syndrome Diseases 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- PSLWZOIUBRXAQW-UHFFFAOYSA-M dimethyl(dioctadecyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC PSLWZOIUBRXAQW-UHFFFAOYSA-M 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 210000004700 fetal blood Anatomy 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 229960002518 gentamicin Drugs 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 208000021760 high fever Diseases 0.000 description 2
- 230000028996 humoral immune response Effects 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 230000002055 immunohistochemical effect Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000009027 insemination Effects 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 210000004731 jugular vein Anatomy 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 238000002690 local anesthesia Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 230000001338 necrotic effect Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 229920001992 poloxamer 407 Polymers 0.000 description 2
- 229920000447 polyanionic polymer Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 230000009103 reabsorption Effects 0.000 description 2
- 238000009589 serological test Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 2
- 210000001215 vagina Anatomy 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
- ZKFNOUUKULVDOB-UHFFFAOYSA-N 1-amino-1-phenylmethyl phosphonic acid Chemical compound OP(=O)(O)C(N)C1=CC=CC=C1 ZKFNOUUKULVDOB-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- QWVRTSZDKPRPDF-UHFFFAOYSA-N 5-(piperidin-1-ylmethyl)-3-pyridin-3-yl-5,6-dihydro-2h-1,2,4-oxadiazine Chemical compound C1CCCCN1CC(N=1)CONC=1C1=CC=CN=C1 QWVRTSZDKPRPDF-UHFFFAOYSA-N 0.000 description 1
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
- 102100027211 Albumin Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 241001227713 Chiron Species 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 241001112695 Clostridiales Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241001137307 Cyprinodon variegatus Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010049927 Dry gangrene Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241000710781 Flaviviridae Species 0.000 description 1
- 208000022555 Genital disease Diseases 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 241000235309 Hagia Species 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 206010022095 Injection Site reaction Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000589929 Leptospira interrogans Species 0.000 description 1
- 241001518154 Leptospira kirschneri serovar Grippotyphosa Species 0.000 description 1
- 206010024769 Local reaction Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 241001147660 Neospora Species 0.000 description 1
- 241000588767 Proteus vulgaris Species 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 108010073443 Ribi adjuvant Proteins 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 241000589970 Spirochaetales Species 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 230000010530 Virus Neutralization Effects 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000035472 Zoonoses Diseases 0.000 description 1
- 210000002718 aborted fetus Anatomy 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 229940024546 aluminum hydroxide gel Drugs 0.000 description 1
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000003975 animal breeding Methods 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 208000008921 border disease Diseases 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 210000004720 cerebrum Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940107161 cholesterol Drugs 0.000 description 1
- 210000001136 chorion Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 230000008094 contradictory effect Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000000899 immune system response Effects 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000006057 immunotolerant effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960003846 melengestrol acetate Drugs 0.000 description 1
- 210000001259 mesencephalon Anatomy 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 1
- 208000010753 nasal discharge Diseases 0.000 description 1
- 230000002956 necrotizing effect Effects 0.000 description 1
- 230000003448 neutrophilic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 210000005059 placental tissue Anatomy 0.000 description 1
- 244000062645 predators Species 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229940007042 proteus vulgaris Drugs 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 208000017443 reproductive system disease Diseases 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 210000004127 vitreous body Anatomy 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
- A61K39/265—Infectious rhinotracheitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/10011—Birnaviridae
- C12N2720/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
- C12N2760/18622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
- C12N2770/24322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/28011—Hepeviridae
- C12N2770/28022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Pulmonology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Toxicology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Description
、血液を通じて体中に広がる。レプトスピラは腎臓と生殖管に向かう傾向があり、目の硝子体液や中枢神経系には少ない。最も一般的な感染手段は、感染した尿、乳、胎盤液との直接的または間接的な接触であるが、性交や卵巣を経由した感染も知られている。家畜がレプトスピラに感染すると、急性の発熱、乳汁分泌欠如、流産が起こったり、未熟で弱い感染した子牛が誕生したりすることがあり、しかも交配が失敗したり妊娠率が低くなったりする可能性がある。感染は抗生物質で治療できるが、授乳または妊娠していない家畜では感染が明らかでないことがある。そのような家畜では腎臓の急性または慢性の感染が起こり、毒性を持った生物を含む尿が放出される。すると今度は、他の動物やその動物の世話をしている人が感染する可能性がある。レプトスピラに対する免疫は血清型特異的である。ワクチンが長年にわたって使われているにもかかわらず、そのほとんどは、弱くて短期間の免疫しか誘導しない。
ばBVDVに対するワクチン組成物も含むことができる。そのような追加活性成分としては、例えばWO 95/12682、WO 99/55366、米国特許第6,060,457号、第6,015,795号、第6,001,613号、第5,593,873号に記載されているものがある。
ティフォーサ、レプトスピラ・ボルグペテルセニイ・ハージョ-プラジトゥノ、レプトスピラ・イクテロヘモルハジア、レプトスピラ・ボルグペテルセニイ・ハージョ-ボビス、レプトスピラ・インターロガンス・ポモナなどである。
対して混合線形モデルを用いることにより、血清中和力価を分析した。分散の分析から得られる最小自乗平均を利用し、幾何平均力価(GMT)を計算した。そのとき、攻撃接種を行なわなかった乳牛のSNデータは除外した。確率の値としてP≦0.05を利用し、統計的有意さを明らかにした。
染に関して全体として92.9%で効果が得られた(表4)。これは、BVDV-1を用いた胎仔攻撃接種に対する同じワクチンでの以前のテストにおける88.9%という保護効果(接種した18頭中の16頭がBVDVの単離に関して陰性であった)に匹敵していた(実施例2を参照のこと)。どちらの研究でも、接種していないプラセボの乳牛で100%の胎仔感染が起こった。これは、接種した乳牛が激しい免疫の攻撃接種を受けたことを示している。
拠から、BVDVに感染した胎仔は、攻撃接種の結果としてウイルス血症になった雌親が流産したことが示唆される。
の)にレプトスピラが存在しているかどうかを調べた。尿と腎臓の培養物にレプトスピラが存在しているかどうかを、標準的な手続きを利用して週に1回、8週間にわたって調べた。標準的なやり方でレプトスピラ蛍光抗体(FA)法を設備の整った獣医学診断センター(コーネル大学、獣医学カレッジ、診断研究室)で実施した。
Claims (11)
- 妊娠中の又は交配前の母牛への投与を介して子牛の持続性胎仔BVDV感染を防御するための免疫原性組成物であって、
修飾された生ウシ・ヘルペス・ウイルス(BHV-1);
修飾された生パラインフルエンザ・ウイルス3型(PI3);
修飾された生ウシ呼吸器多核体ウイルス(BRSV);
不活性化ウシ・ウイルス性下痢症ウイルス1型(BVDV-1);
不活性化ウシ・ウイルス性下痢症ウイルス2型(BVDV-2);および
獣医学的に許容される基剤を含み、ここで前記基剤がサポニン、ステロール、及び水中油型エマルジョンを含む、免疫原性組成物。 - 前記BVDV-1がBVDV5960株(国立動物疾患センター、米国農業省、エイムズ、アイオワ州)である、請求項1に記載の免疫原性組成物。
- 前記BVDV-2がBVDV53637株(ATCC PTA-4859)である、請求項1に記載の免疫原性組成物。
- 前記サポニンがクイルAであり、前記水中油型エマルジョンがレシチンおよび鉱油を含み;前記ステロールがコレステロールである、請求項1に記載の免疫原性組成物。
- エマルジョンが微流体化されている、請求項4に記載の免疫原性組成物。
- 妊娠中の又は交配前の母牛への投与を介して子牛の持続性胎仔BVDV感染を防御するためのワクチン組成物であって、
修飾された生ウシ・ヘルペス・ウイルス(BHV-1);
修飾された生パラインフルエンザ・ウイルス3型(PI3);
修飾された生ウシ呼吸器多核体ウイルス(BRSV);
不活性化ウシ・ウイルス性下痢症ウイルス1型(BVDV-1);
不活性化ウシ・ウイルス性下痢症ウイルス2型(BVDV-2);および
レプトスピラ・カニコーラ、レプトスピラ・グリッポティフォーサ、レプトスピラ・ボルグペテルセニイ・ハージョ-プラジトゥノ、レプトスピラ・イクテロヘモルハジア、レプトスピラ・インターロガンス・ポモナ、レプトスピラ・ボルグペテルセニイ・ハージョ-ボビス、レプトスピラ・ブラチスラバ、カンピロバクター・フィタス、ネオスポラ・カニナム、トリコモナス・フィタス、マイコプラズマ・ボビス、ヘモフィルス・ソムナス、マンハイミア・ヘモリティカ、およびパスツレラ・ムルトシダからなる群から選択される少なくとも一つの抗原;および
獣医学的に許容される基剤を含み、ここで前記基剤がサポニン、ステロール、及び水中油型エマルジョンを含む、ワクチン組成物。 - 前記サポニンがクイルAであり、前記水中油型エマルジョンがレシチンおよび鉱油を含み;前記ステロールがコレステロールである、請求項6に記載のワクチン組成物。
- 前記エマルジョンが微流体化されている、請求項7に記載のワクチン組成物。
- 子牛においてBVDV感染の防御または治療のために有効量である請求項1から8のいずれか1項に記載の組成物の使用を含む、医薬の製造方法。
- 防御または治療が前記子牛の母牛への投与を介するものである、請求項9に記載の方法。
- 前記動物が、乳牛、または未経産雌牛である、請求項10に記載の方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40596902P | 2002-08-26 | 2002-08-26 | |
US60/405,969 | 2002-08-26 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004530459A Division JP2006501237A (ja) | 2002-08-26 | 2003-08-14 | 家畜の呼吸系と生殖系の感染症に対するワクチン |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015113008A Division JP2015172069A (ja) | 2002-08-26 | 2015-06-03 | 家畜の呼吸系と生殖系の感染症に対するワクチン |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2012092126A JP2012092126A (ja) | 2012-05-17 |
JP5785073B2 true JP5785073B2 (ja) | 2015-09-24 |
Family
ID=31946951
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004530459A Pending JP2006501237A (ja) | 2002-08-26 | 2003-08-14 | 家畜の呼吸系と生殖系の感染症に対するワクチン |
JP2009118662A Withdrawn JP2009215309A (ja) | 2002-08-26 | 2009-05-15 | 家畜の呼吸系と生殖系の感染症に対するワクチン |
JP2011275303A Expired - Lifetime JP5785073B2 (ja) | 2002-08-26 | 2011-12-16 | 家畜の呼吸系と生殖系の感染症に対するワクチン |
JP2015113008A Pending JP2015172069A (ja) | 2002-08-26 | 2015-06-03 | 家畜の呼吸系と生殖系の感染症に対するワクチン |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004530459A Pending JP2006501237A (ja) | 2002-08-26 | 2003-08-14 | 家畜の呼吸系と生殖系の感染症に対するワクチン |
JP2009118662A Withdrawn JP2009215309A (ja) | 2002-08-26 | 2009-05-15 | 家畜の呼吸系と生殖系の感染症に対するワクチン |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015113008A Pending JP2015172069A (ja) | 2002-08-26 | 2015-06-03 | 家畜の呼吸系と生殖系の感染症に対するワクチン |
Country Status (32)
Country | Link |
---|---|
US (4) | US20040081666A1 (ja) |
EP (2) | EP1536830A1 (ja) |
JP (4) | JP2006501237A (ja) |
KR (2) | KR20050062542A (ja) |
CN (1) | CN1315534C (ja) |
AP (1) | AP2005003238A0 (ja) |
AR (1) | AR041047A1 (ja) |
AT (1) | ATE533506T1 (ja) |
AU (2) | AU2003263390B2 (ja) |
BR (1) | BR0313806A (ja) |
CA (1) | CA2496750C (ja) |
EA (1) | EA011578B1 (ja) |
GT (1) | GT200300180A (ja) |
HK (1) | HK1078457A1 (ja) |
HR (2) | HRP20050192B1 (ja) |
IS (1) | IS7672A (ja) |
MA (1) | MA27388A1 (ja) |
ME (1) | ME00810B (ja) |
MX (1) | MXPA05002255A (ja) |
NO (1) | NO20050603L (ja) |
NZ (2) | NZ565206A (ja) |
OA (1) | OA12915A (ja) |
PA (1) | PA8581101A1 (ja) |
PE (1) | PE20040420A1 (ja) |
PL (1) | PL216541B1 (ja) |
RS (1) | RS20050177A (ja) |
TN (1) | TNSN05059A1 (ja) |
TW (1) | TWI272105B (ja) |
UA (1) | UA94689C2 (ja) |
UY (1) | UY27948A1 (ja) |
WO (1) | WO2004017990A1 (ja) |
ZA (1) | ZA200501171B (ja) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7179473B2 (en) | 1998-06-05 | 2007-02-20 | Boehringer Ingelheim Vetmedica Gmbh | Attenuated pestiviruses |
US7135561B2 (en) | 2001-09-06 | 2006-11-14 | Boehringer Ingelheim Vetmedica Gmbh | Infectious bovine viral diarrhea virus clone |
MXPA05002255A (es) * | 2002-08-26 | 2005-06-08 | Pfizer Prod Inc | Vacunas para infecciones del sistema respiratorio y reproductor en ganado. |
US20050089533A1 (en) * | 2003-01-29 | 2005-04-28 | Joseph Frantz | Canine vaccines against Bordetella bronchiseptica |
US7563449B2 (en) * | 2003-04-21 | 2009-07-21 | Pfizer Inc, | Methods for reducing cattle reproductive diseases |
US7361357B2 (en) * | 2003-07-29 | 2008-04-22 | Pfizer Inc. | Safe mutant viral vaccines |
WO2005058356A2 (en) * | 2003-12-17 | 2005-06-30 | Wyeth | Methods for porducing storage stable viruses and immunogenic compositions thereof |
SI1742659T1 (sl) * | 2004-04-05 | 2013-07-31 | Zoetis P Llc | Mikrofluidizirane emulzije olja v vodi in sestavki cepiv |
US7572455B2 (en) * | 2004-05-19 | 2009-08-11 | Boehringer Ingelheim Vetmedica Gmbh | Vaccine comprising an attenuated pestivirus |
UY29915A1 (es) * | 2005-11-15 | 2007-06-29 | Boehringer Ingelheim Vetmed | Vacuna combinada que comprende un virus atenuado de la diarrea viral bovina |
RS54981B1 (sr) | 2006-09-11 | 2016-11-30 | Zoetis P Llc | Bakterini tretirani toplotom i vakcine tipa emulzije izrađene od ovakvih bakterina tretiranih toplotom |
WO2008036747A2 (en) * | 2006-09-21 | 2008-03-27 | Amarillo Biosciences, Inc. | Composition and method for immunomodulation |
US7803527B2 (en) * | 2007-10-31 | 2010-09-28 | Novartis Ag | Inactivated bovine herpes virus-1 and methods |
EP2224951B1 (en) * | 2007-12-21 | 2019-10-30 | Zoetis Services LLC | Heat treated bacterins, and emulsion vaccines prepared from such heat treated bacterins |
UY31930A (es) * | 2008-06-25 | 2010-01-29 | Boheringer Ingelheim Pharma Kg | Pestivirus atenuados recombinantes, en particular a csfv, bvdv o bdv atenuado recombinante |
US8637046B2 (en) | 2008-10-03 | 2014-01-28 | Cornell University | Bovine herpes virus-1 compositions, vaccines and methods |
US8846054B2 (en) * | 2009-01-09 | 2014-09-30 | Boehringer Ingelheim Vetmedica, Inc. | Method of treating pregnant cows and/or heifers |
MX345704B (es) * | 2011-06-10 | 2017-02-10 | Novartis Tiergesundheit Ag | Vacuna bovinas y métodos. |
RU2522780C2 (ru) * | 2012-07-27 | 2014-07-20 | Государственное научное учреждение Всероссийский научно-исследовательский институт ветеринарной санитарии, гигиены и экологии Российской академии сельскохозяйственных наук | Способ получения вакцины против инфекционного ринотрахеита крупного рогатого скота |
US9314519B2 (en) | 2012-08-21 | 2016-04-19 | Intervet Inc. | Liquid stable virus vaccines |
US20140147475A1 (en) | 2012-11-29 | 2014-05-29 | Antonius Arnoldus Christiaan Jacobs | Vaccine to protect a ruminant against pneumonia caused by pasteurella multocida |
US9393298B2 (en) | 2013-03-15 | 2016-07-19 | Intervet Inc. | Liquid stable bovine virus vaccines |
US9480739B2 (en) * | 2013-03-15 | 2016-11-01 | Intervet Inc. | Bovine virus vaccines that are liquid stable |
EP2976102B1 (en) | 2013-03-18 | 2019-12-11 | Intervet International B.V. | Vaccine to protect a ruminant against pneumonia caused by mannheimia haemolytica |
AR097762A1 (es) | 2013-09-27 | 2016-04-13 | Intervet Int Bv | Formulaciones secas de vacunas que son estables a temperatura ambiente |
AR099470A1 (es) | 2014-02-17 | 2016-07-27 | Intervet Int Bv | Vacunas de virus de aves de corral líquidas |
TWI670085B (zh) | 2014-02-19 | 2019-09-01 | 荷蘭商英特威國際公司 | 液體穩定之豬病毒疫苗 |
EP3402878A1 (en) | 2016-01-11 | 2018-11-21 | Zoetis Services LLC | Novel cross protective vaccine compositions for porcine epidemic diarrhea virus |
BR112018069371A2 (pt) | 2016-03-21 | 2019-01-22 | South Dakota Board Of Regents | construção de ácido nucleico, vetor, vacina ou composição imunogênica, método de entrega de uma vacina, método de produção de uma construção de ácido nucleico e método para conferir imunidade contra um antígeno |
JP2019533995A (ja) | 2016-10-05 | 2019-11-28 | ゾエティス・サービシーズ・エルエルシー | 強力な生ワクチンとして使用するための安定に脱水された原生動物を提供する凍結乾燥方法 |
RU2643335C1 (ru) * | 2016-11-14 | 2018-01-31 | Федеральное государственное бюджетное образовательное учреждение высшего образования Санкт-Петербургская государственная академия ветеринарной медицины (ФГБОУ ВПО СПбГ АВМ) | Инактивированная бивалентная гидроокись алюминиевая вакцина против кампилобактериоза собак |
GB201703529D0 (en) | 2017-03-06 | 2017-04-19 | Cambridge Entpr Ltd | Vaccine composition |
CN110317749B (zh) * | 2019-06-19 | 2021-01-22 | 山东省农业科学院奶牛研究中心 | 一株牛支原体强毒株及其应用 |
RU2764220C1 (ru) * | 2020-12-02 | 2022-01-14 | Федеральное государственное бюджетное научное учреждение "Краснодарский научный центр по зоотехнии и ветеринарии" ФГБНУ КНЦЗВ | Способ предупреждения риска заболевания парагриппом-3 у телят |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3634587A (en) * | 1969-11-06 | 1972-01-11 | Ralston Purina Co | Method of immunizing cattle against bovine respiratory disease syndrome |
BE759425A (fr) * | 1969-11-28 | 1971-05-25 | Mebus Charles A | Vaccins contre la diarrhee du veau, leur preparation et emploi |
US5593873A (en) | 1986-01-27 | 1997-01-14 | Syntro Corporation | Recombinant infectious bovine rhinotracheitis virus |
US5084269A (en) | 1986-11-06 | 1992-01-28 | Kullenberg Fred W | Adjuvant for dose treatment with antigens |
EP0273512B1 (en) * | 1986-12-19 | 1991-02-27 | Duphar International Research B.V | Stabilised adjuvant suspension comprising dimethyl dioctadecyl ammonium bromide |
US6291228B1 (en) * | 1988-08-03 | 2001-09-18 | Vericore Limited | Vaccine |
GB8818415D0 (en) * | 1988-08-03 | 1988-09-07 | Animal Health Inst | Vaccine |
MX9301736A (es) | 1992-03-30 | 1994-01-31 | Smithkline Beecham Corp | Vacuna de bacterina-toxoide de pasteurella haemolytica tipo a-1. |
US5951988A (en) * | 1993-03-30 | 1999-09-14 | University Of Saskatchewan | Adjuvant formulation with enhanced immunogenic activity, and related compositions and methods |
CA2172815A1 (en) | 1993-11-05 | 1995-05-11 | Elizabeth J. Haanes | Viral vector with bovine viral diarrhea virus (bvdv) antigens |
KR100374434B1 (ko) * | 1994-05-10 | 2003-06-09 | 와이어쓰 | 변형된소호흡관련합포체바이러스(brsv)생백신조성물 |
US5709865A (en) | 1994-11-10 | 1998-01-20 | Biostar Inc. | Immunogenic composition against Bovine Viral Diarrhea Virus II glycoprotein 53 (BVDV-II gp53) |
US6001613A (en) | 1996-05-24 | 1999-12-14 | Board Of Regents Of University Of Nebraska | Plasmid bearing a cDNA copy of the genome of bovine viral diarrhea virus, chimeric derivatives thereof, and method of producing an infectious bovine viral diarrhea virus using said plasmid |
US6060457A (en) | 1996-06-20 | 2000-05-09 | Universite De Montreal | DNA plasmid vaccine for immunization of animals against BVDV |
BR9803232A (pt) * | 1997-08-26 | 2000-01-11 | Pfizer Prod Inc | Vaicna de neospora. |
CA2302554C (en) * | 1997-09-05 | 2007-04-10 | Smithkline Beecham Biologicals S.A. | Oil in water emulsions containing saponins |
UA78180C2 (uk) * | 1997-10-03 | 2007-03-15 | Меріаль | Кільцевий вірус свині типу ii, вакцини та діагностичні реагенти |
EP0924295A3 (en) * | 1997-12-04 | 2001-05-16 | Pfizer Products Inc. | DNA encoding neospora dihydrofolate reductase-thymidylate synthase |
EP1071454A1 (en) | 1998-04-24 | 2001-01-31 | Washington University | Chimeras of hepatitis c virus and bovine viral diarrhea virus |
AU769539B2 (en) * | 1999-01-29 | 2004-01-29 | Zoetis Services Llc | Adjuvants for use in vaccines |
MXPA05002255A (es) * | 2002-08-26 | 2005-06-08 | Pfizer Prod Inc | Vacunas para infecciones del sistema respiratorio y reproductor en ganado. |
ES2365832T3 (es) | 2007-03-05 | 2011-10-11 | Cadila Healthcare Limited | Composiciones que comprenden conjugados de peg-interferón alfa y rafinosa como crioprotector. |
-
2003
- 2003-08-14 MX MXPA05002255A patent/MXPA05002255A/es active IP Right Grant
- 2003-08-14 JP JP2004530459A patent/JP2006501237A/ja active Pending
- 2003-08-14 KR KR1020057003230A patent/KR20050062542A/ko active Search and Examination
- 2003-08-14 EP EP03792580A patent/EP1536830A1/en not_active Ceased
- 2003-08-14 CA CA2496750A patent/CA2496750C/en not_active Expired - Lifetime
- 2003-08-14 RS YUP-2005/0177A patent/RS20050177A/sr unknown
- 2003-08-14 NZ NZ565206A patent/NZ565206A/en not_active IP Right Cessation
- 2003-08-14 EA EA200500275A patent/EA011578B1/ru not_active IP Right Cessation
- 2003-08-14 PL PL375548A patent/PL216541B1/pl unknown
- 2003-08-14 AP AP2005003238A patent/AP2005003238A0/xx unknown
- 2003-08-14 UA UAA200501771A patent/UA94689C2/ru unknown
- 2003-08-14 EP EP06122758A patent/EP1743652B1/en not_active Expired - Lifetime
- 2003-08-14 BR BR0313806-2A patent/BR0313806A/pt not_active Application Discontinuation
- 2003-08-14 OA OA1200500058A patent/OA12915A/en unknown
- 2003-08-14 CN CNB038203162A patent/CN1315534C/zh not_active Expired - Lifetime
- 2003-08-14 AU AU2003263390A patent/AU2003263390B2/en not_active Expired
- 2003-08-14 NZ NZ538394A patent/NZ538394A/en not_active IP Right Cessation
- 2003-08-14 KR KR1020067022893A patent/KR20060116037A/ko active Search and Examination
- 2003-08-14 WO PCT/IB2003/003633 patent/WO2004017990A1/en active Application Filing
- 2003-08-14 ME MEP-2009-213A patent/ME00810B/me unknown
- 2003-08-14 AT AT06122758T patent/ATE533506T1/de active
- 2003-08-20 TW TW092122872A patent/TWI272105B/zh not_active IP Right Cessation
- 2003-08-22 UY UY27948A patent/UY27948A1/es not_active Application Discontinuation
- 2003-08-22 PE PE2003000857A patent/PE20040420A1/es not_active Application Discontinuation
- 2003-08-25 PA PA20038581101A patent/PA8581101A1/es unknown
- 2003-08-25 GT GT200300180A patent/GT200300180A/es unknown
- 2003-08-25 AR ARP030103054A patent/AR041047A1/es unknown
- 2003-08-26 US US10/647,919 patent/US20040081666A1/en not_active Abandoned
-
2005
- 2005-01-27 IS IS7672A patent/IS7672A/is unknown
- 2005-02-03 NO NO20050603A patent/NO20050603L/no not_active Application Discontinuation
- 2005-02-09 ZA ZA200501171A patent/ZA200501171B/en unknown
- 2005-02-25 TN TNP2005000059A patent/TNSN05059A1/fr unknown
- 2005-02-25 MA MA28121A patent/MA27388A1/fr unknown
- 2005-02-28 HR HRP20050192AA patent/HRP20050192B1/hr not_active IP Right Cessation
- 2005-11-18 HK HK05110344A patent/HK1078457A1/xx not_active IP Right Cessation
-
2007
- 2007-08-30 US US11/897,421 patent/US20070298053A1/en not_active Abandoned
-
2008
- 2008-12-16 AU AU2008258154A patent/AU2008258154B2/en not_active Expired
-
2009
- 2009-05-14 HR HR20090271A patent/HRP20090271A2/xx not_active Application Discontinuation
- 2009-05-15 JP JP2009118662A patent/JP2009215309A/ja not_active Withdrawn
-
2010
- 2010-06-22 US US12/820,566 patent/US9662384B2/en active Active
-
2011
- 2011-12-16 JP JP2011275303A patent/JP5785073B2/ja not_active Expired - Lifetime
-
2012
- 2012-12-28 US US13/729,206 patent/US20130129779A1/en not_active Abandoned
-
2015
- 2015-06-03 JP JP2015113008A patent/JP2015172069A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5785073B2 (ja) | 家畜の呼吸系と生殖系の感染症に対するワクチン | |
US20070154943A1 (en) | Methods for preventing cattle reproductive diseases | |
EP1727562B1 (en) | Method of vaccination against testicular bvdv infection | |
MXPA06010631A (en) | Method of vaccination against testicular bvdv infection |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20121122 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20130121 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130214 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20130423 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20130423 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130801 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131101 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140616 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140912 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140918 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141216 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20141216 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20150204 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150603 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20150603 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20150629 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150714 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150723 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5785073 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |